Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andreas G Moraitis, MD
Corcept Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site #150, Stanford Cancer Center
Stanford, California, United States
- Site #007, Moffitt Cancer Center
Tampa, Florida, United States
- Site #074, University of Michigan Medical School
Ann Arbor, Michigan, United States
- Site #030 Mayo Clinic
Rochester, Minnesota, United States
- Site #051, Memorial Hospital
New York, New York, United States
- Site #183, the University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2020
- Primary completion
- 17 Oct 2023
- Completion
- 12 Jan 2024
- Last update posted
- 23 Feb 2024
- Registered enrollment
- 15
- Registry id
- NCT04373265
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.